Abstract. Renal cell carcinoma (RCC) accounts for 85-90% of kidney cancers, which in turn account for 2-3% of all malignant tumors in adults. Xp11.2 translocation/TFE3 gene fusion RCC is currently classified as a distinct type of RCC. RCC is capable of invading the renal vein and inferior vena cava to form a tumor thrombus. The incidence of RCC with tumor thrombi within the renal vein or inferior vena cava is 7-10% in China. In the present case report, the patient underwent radical resection of the renal tumor and removal of the tumor thrombus, assisted by cardiopulmonary bypass, for the treatment of Xp11.2 translocation/TFE3 gene fusion RCC. The patient was followed-up for 12 months subsequent to treatment. The patient’s renal function remained within the normal range, and computed tomography examination revealed no evidence of disease recurrence or metastases. The present case report aimed to provide a reference for the development of guidelines for the diagnosis and treatment of Xp11.2 translocation/TFE3 gene fusion RCC.

Introduction

Kidney cancer accounts for 2-3% of all malignant tumors in adults, with renal cell carcinoma (RCC) accounting for 85-90% of kidney cancers (1). According to the World Health Organization classification criteria for renal cancer, published in 2004 (2), RCC with Xp11.2 translocation/TFE3 gene fusion is classified as a distinct type of RCC. RCC with Xp11.2 translocation/TFE3 gene fusion primarily occurs in adolescents, and demonstrates no significant gender variation (2). The malignancy of RCC with Xp11.2 translocation/TFE3 gene fusion is considered to be relatively low. Therefore, few cases of advanced tumors have been previously reported (2).

RCC is capable of invading the renal vein and inferior vena cava to form a tumor thrombus; in China, this occurs in 7-10% of RCC cases (3). It is widely accepted that tumor thrombus of the inferior vena cava is not a decisive indicator for determination of the prognosis of patients with RCC (4). Surgery is typically the first choice of treatment for RCC, due to its insensitivity to chemotherapy and radiotherapy. Clinical studies have demonstrated a certain efficacy of multi-kinase inhibitors, such as sunitinib, sorafenib and mTOR/MET kinase inhibitor, in treating rapidly progressive metastatic Xp11.2 RCC in adult patients (5,6). However, the optimal treatment approach for Xp11.2 RCC remains to be determined.

The current study presents the case of a patient with Xp11.2 translocation/TFE3 gene fusion RCC, who underwent radical resection of a renal tumor and removal of the tumor thrombus, assisted by cardiopulmonary bypass.

Case report

The current report presents the case of a 46-year-old male, who was admitted to the Nanjing Drum Tower Hospital (Nanjing, China) in September 2013, due to right abdominal pain. Renal magnetic resonance imaging (MRI) results suggested a diagnosis of RCC with hemorrhage, accompanied by an inferior vena cava tumor thrombus and enlarged retroperitoneal lymph nodes. Vascular ultrasound examination indicated that a tumor thrombus had formed within the inferior vena cava, and that it extended to the level of the diaphragm. Following the exclusion of surgical contraindications, radical resection of the right kidney, and removal of the tumor thrombus within the inferior vena cava under cardiopulmonary bypass, were performed. Briefly, following exposure of the right kidney and inferior vena cava, cardiopulmonary bypass was established via intubation of the ascending aorta, inferior vena cava and right atrium. The
tumor thrombus was removed by dissecting the vena cava following relocation of the tumor thrombus from the superior vena cava to the inferior vena cava. Heparin (400 U/kg) and low-dose protamine (2 mg/kg; for the reversal of heparin) were administered during and following the cardiopulmonary bypass. Subsequently, the right kidney was resected.

Combined with the results of TFE3 gene fusion protein immunohistochemistry and fluorescent in situ hybridization (FISH), a diagnosis of Xp11.2 translocation/TFE3 gene fusion-related RCC was considered (Fig. 1A-D). The patient was discharged two weeks subsequent to surgery. Chemotherapy was administered following discharge of the patient from hospital; the patient was initially started on oral sorafenib (400 mg, twice daily), and 6 months later was switched to oral sunitinib (50 mg/day) for 4 weeks on and 2 weeks off.

The patient was followed up for 12 months subsequent to treatment. The patient's renal function remained within the normal range, while computed tomography examination revealed no evidence of disease recurrence or metastases. Therefore, the possibility of recurrence during this follow-up period was ruled out. However, determining the long-term prognosis of patient still requires long-term follow-up.

Discussion

According to the tumor thrombus classification devised by Neves and Zincke (7), based on the extent of dissection, the tumor thrombus in the present case was defined within the third classification, and described as a tumor thrombus within the inferior vena cava, extending to the level below the diaphragm. MRI, which demonstrates advantages for the detection of vena cava tumor thrombi, was utilized in the present case to detect and evaluate the vena cava tumor thrombus (8). Following exclusion of the presence of distant metastasis, surgery was performed.

It has been accepted that surgical removal of the tumor and thrombus is the typical first choice treatment strategy for non-metastatic RCC, even with the co-occurrence of an inferior vena cava thrombus (9). In the present case, cardiopulmonary bypass was utilized to assist with the removal of the tumor thrombus within the inferior vena cava (Fig. 1B). Cardiopulmonary bypass may be able to extend operating times and surgical space for surgeons (10). In addition, cardiopulmonary bypass markedly reduces the potential risk of bleeding during surgery on large blood vessels, simplifying the surgical resection of tumor thrombi within the inferior
vena cava, and those located within the right atrium (9). It is widely accepted that immunohistochemical staining of certain proteins specifically expressed in Xp11.2 translocation/TFE3 gene fusion RCC, including TFE3 gene fusion-associated protein, is the primary method for diagnosis of this type of tumor (11,12). Argani et al (13) reported that the sensitivity and specificity of immunohistochemistry in the diagnosis of tumors with Xp11.2 translocation/TFE3 gene fusion in the urinary system, and additional systems, was 99.6 and 97.5%, respectively. In the present case, the tumor weakly expressed P504S, while strongly expressing CD117, human melanoma black 45 and TFE3 (Fig. 1C).

To date, eight specific genotypes have been reported in Xp11.2 translocation/TFE3 gene fusion RCC, and in three of these the site of gene fusion cannot be clearly identified. Xp11.2 translocation/TFE3 gene fusion RCC accounts for ~1% of RCC diagnoses in adult patients (14). FISH with polyclonal break-apart probes, has been used as a rapid and accurate diagnostic method for detecting TFE3 gene fracture in tumor tissue. This is due to this method's specific ability to bind with each end of fragments of TFE3 DNA (15,16). In the present case, FISH was used to confirm the diagnosis of Xp11.2 translocation/TFE3 gene fusion RCC. As indicated in Fig. 1D, tumor cells demonstrated a fusion signal (yellow) and a pair of red and green split signals, representing TFE3 gene translocations in the X chromosome. This result confirmed that FISH may be useful as an alternative, effective method for the diagnosis of Xp11.2 translocation/TFE3 gene fusion RCC.

Follow-up of the current patient is ongoing. To the best of our knowledge, the present case is the first to report the successful surgical treatment of Xp11.2 translocation/TFE3 gene fusion RCC with inferior vena cava tumor thrombus surgery, using cardiopulmonary bypass. The present report may provide a reference for the development of guidelines for the diagnosis and treatment of Xp11.2 translocation/TFE3 gene fusion RCC.

References